Clinical bottom line
Rare inherited epileptic encephalopathies (EEs) represent a heterogeneous group of severe neurodevelopmental disorders characterized by early-onset, refractory seizures and developmental impairment. Advances in genetic diagnostics and molecular understanding have enabled precision medicine approaches that tailor treatment based on specific pathogenic variants. Emerging evidence supports integrating comprehensive genomic testing early in the diagnostic pathway to identify monogenic causes, which can inform targeted therapies and improve outcomes. However, clinical evidence remains limited by small cohorts and variable genotype-phenotype correlations. Clinicians should consider precision medicine strategies as adjuncts to standard care, with ongoing evaluation of efficacy and safety.
What the evidence shows
Inherited developmental and epileptic encephalopathies are increasingly recognized as genetically diverse disorders, with pathogenic variants identified in genes encoding ion channels, synaptic proteins, and metabolic enzymes (Bartolini et al., 2021). The genetic landscape continues to expand, with next-generation sequencing revealing novel mutations and enabling earlier diagnosis (Thakran et al., 2020). Precision medicine approaches aim to modify disease course by targeting underlying molecular mechanisms rather than solely controlling seizures (Samanta et al., 2026).
Recent reviews emphasize the utility of comprehensive genetic testing, including whole-exome and whole-genome sequencing, in infants presenting with unexplained epileptic encephalopathies (Martinez Vergara et al., 2025; Myers et al., 2022). Identification of specific gene mutations can guide treatment choices; for example, SCN1A mutations associated with Dravet syndrome inform avoidance of sodium channel blockers and consideration of novel therapies like cannabidiol or fenfluramine (Myers et al., 2022). Similarly, precision therapeutics targeting metabolic defects or synaptic dysfunction are under active investigation (Samanta et al., 2026).
Clinical case series highlight the phenotypic variability and the challenge of genotype-phenotype correlations, underscoring the need for individualized management plans (Maarouf et al., 2026). Mechanistic studies using in vitro and animal models have elucidated pathogenic pathways, supporting the rationale for targeted interventions (Galanopoulou et al., 2019). However, evidence from controlled clinical trials remains sparse, and many precision therapies are still investigational or off-label.
Integration of evidence-based medicine with precision approaches is advocated to optimize clinical decision-making, balancing molecular insights with clinical context and patient-specific factors (Chow et al., 2018). Multidisciplinary care involving neurologists, geneticists, and pharmacologists is critical to interpret genetic findings and implement tailored treatments safely.
Caveats and uncertainty
Despite promising advances, several challenges limit the current clinical application of precision medicine in rare inherited EEs. The rarity and heterogeneity of these disorders result in small, often retrospective cohorts, limiting the generalizability of findings (Bartolini et al., 2021). Many identified variants remain classified as variants of uncertain significance, complicating treatment decisions (Martinez Vergara et al., 2025).
There is incomplete understanding of the natural history and long-term outcomes associated with specific genotypes, and the impact of precision therapies on developmental trajectories is not well established (Myers et al., 2022). Potential adverse effects and drug interactions require careful monitoring, especially when using novel or repurposed agents (Samanta et al., 2026).
Access to comprehensive genetic testing and precision therapeutics may be limited by cost, availability, and regional disparities. Ethical considerations around genetic information and treatment expectations also warrant attention.
How this may change practice
Clinicians managing infants and children with suspected inherited epileptic encephalopathies should consider early referral for comprehensive genetic evaluation to facilitate diagnosis and inform treatment. Precision medicine approaches may enable more rational selection of antiseizure medications and emerging targeted therapies, potentially improving seizure control and neurodevelopmental outcomes.
Ongoing education and collaboration with genetic specialists are essential to interpret complex genetic data and integrate it into individualized care plans. Clinicians should remain cautious, recognizing current evidence limitations and the need for longitudinal follow-up and participation in clinical trials.
Incorporating precision medicine into routine practice may also prompt development of multidisciplinary care pathways and support services tailored to the needs of these patients and families.